IntactiWiki

Histogen: Difference between revisions

← Older editNewer edit →
WikiAdmin (talk | contribs)
administrator, administrators, Bureaucrats, Interface administrators, Administrators
22,834 edits
WikiAdmin (talk | contribs)
administrator, administrators, Bureaucrats, Interface administrators, Administrators
22,834 edits
m add interlanguage link
WikiAdmin (talk | contribs)
administrator, administrators, Bureaucrats, Interface administrators, Administrators
22,834 edits
mNo edit summary
Line 18: Line 18:


On October 2012 Histogen announced preliminary data from a combined Phase 1/2 clinical trial. In this trial, patients aged 40-59 showed a mean increase of 39 percent in so-called terminal hair, as opposed to fine hair called vellus hair. Hair regrowth took place across all regions of the scalp.<ref name="hairgrowth"/>
On October 2012 Histogen announced preliminary data from a combined Phase 1/2 clinical trial. In this trial, patients aged 40-59 showed a mean increase of 39 percent in so-called terminal hair, as opposed to fine hair called vellus hair. Hair regrowth took place across all regions of the scalp.<ref name="hairgrowth"/>
== Gail K. Naughton ==
Naughton was president and COO of [[Advanced Tissue Sciences]], which produced a living skin product call [[Dermagraft]] used to help healing of diabetic foot ulcers. Dermagraft is now being made in San Diego by a subsidiary of [[Shire]], a medical company based in Dublin, Ireland.
Naughton founded Histogen in 2007, when she was dean of San Diego State University's College of Business Administration. Naughton, who had been dean since 2002, left in 2010 to focus on Histogen.
<ref>{{REFweb
|last=
|first=
|date=2012-09-05
|title=U.S. Patent issued for Histogen's Novel Cell Growth Process
|url=http://www.histogen.com/aboutus/news_events.htm#37
|publisher=Histogen
|accessdate=2012-11-16
}}</ref>


{{REF}}
{{REF}}
Retrieved from "https://en.intactiwiki.org/wiki/Histogen"